What is Leerink Partnrs' Forecast for RARE Q1 Earnings?

Key Points

• Leerink Partners predicts Ultragenyx Pharmaceutical will report Q1 2026 earnings per share of ($1.30), with full-year estimates reaching ($5.18) per share.
• Ultragenyx shares received various price targets from analysts, including a drop from $112.00 to $105.00 by Cantor Fitzgerald, while HC Wainwright raised it to $80.00, showcasing a mixed market outlook.
• Institutional investors now own 97.67% of Ultragenyx Pharmaceutical's stock, indicating strong institutional confidence in the company's future despite recent earnings challenges.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Tuesday, August 5th. Leerink Partnrs analyst J. Schwartz forecasts that the biopharmaceutical company will post earnings per share of ($1.30) for the quarter. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical's Q2 2026 earnings at ($1.12) EPS, Q3 2026 earnings at ($1.21) EPS, Q4 2026 earnings at ($0.95) EPS and FY2027 earnings at $0.42 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. During the same quarter last year, the business earned ($1.52) earnings per share. The company's quarterly revenue was up 13.2% on a year-over-year basis.

A number of other equities analysts have also commented on the stock. HC Wainwright upgraded shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective for the company in a research report on Monday, July 28th. Canaccord Genuity Group cut their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research report on Friday. Morgan Stanley cut their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Wells Fargo & Company cut their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. Finally, Wedbush cut their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Trading Down 1.0%

Shares of RARE stock traded down $0.29 during trading hours on Thursday, reaching $27.54. The stock had a trading volume of 1,527,932 shares, compared to its average volume of 2,814,751. The stock's fifty day simple moving average is $33.32 and its 200 day simple moving average is $36.78. Ultragenyx Pharmaceutical has a 12 month low of $25.81 and a 12 month high of $60.37. The firm has a market capitalization of $2.65 billion, a PE ratio of -4.98 and a beta of 0.25.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in RARE. Price T Rowe Associates Inc. MD boosted its holdings in shares of Ultragenyx Pharmaceutical by 28.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock valued at $116,559,000 after buying an additional 706,519 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Ultragenyx Pharmaceutical by 81.6% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock valued at $77,815,000 after purchasing an additional 965,919 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock valued at $74,419,000 after purchasing an additional 5,400 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 4.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company's stock valued at $62,291,000 after acquiring an additional 66,394 shares during the period. Finally, Deutsche Bank AG grew its stake in shares of Ultragenyx Pharmaceutical by 0.5% during the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock valued at $61,611,000 after acquiring an additional 8,385 shares during the period. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.